Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.52 |
| ▸ | HTT | P42858 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.47 |
| ▸ | RELA | Q04206 | 1/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18170316 | 0.83 | SMN1; SMN2 (0.59) | NPC1HTTLMNASMN1; SMN2RAB9A | |
| SCHEMBL27814558 | 0.78 | CYP3A4 (0.60) | NPC1HTTLMNASMN1; SMN2RAB9A | |
| SCHEMBL4779632 | 0.78 | SMN1; SMN2 (0.62) | NPC1HTTLMNASMN1; SMN2RAB9A | |
| SCHEMBL27683482 | 0.76 | CYP3A4 (0.53) | NPC1LMNASMN1; SMN2KMT2ACYP3A4 | |
| SCHEMBL26528807 | 0.76 | NFKB1 (0.72) | NPC1HTTLMNARAB9AKMT2A | |
| SCHEMBL224315 | 0.76 | NPC1 (0.83) | NPC1HTTLMNASMN1; SMN2RAB9A | |
| SCHEMBL5624104 | 0.75 | SMN1; SMN2 (0.56) | NPC1HTTLMNASMN1; SMN2RAB9A | |
| SCHEMBL4771241 | 0.74 | SMN1; SMN2 (0.67) | NPC1HTTLMNASMN1; SMN2RAB9A | |
| SCHEMBL4638387 | 0.73 | MAPK1 (0.50) | HTTSMN1; SMN2KMT2ACYP3A4CYP2D6 | |
| SCHEMBL392612 | 0.73 | NPC1 (0.62) | NPC1HTTLMNASMN1; SMN2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7226945-B2 | Estrogen receptor-β ligands | ASTRAZENECA AB (SE) | 2007-06-05 | — | — | US | disclosed |
| US-7226945-B2 | Estrogen receptor-β ligands | ASTRAZENECA AB (SE) | 2007-06-05 | — | — | US | disclosed |
| US-7226945-B2 | Estrogen receptor-β ligands | ASTRAZENECA AB (SE) | 2007-06-05 | — | — | US | disclosed |
| US-20050043350-A9 | Estrogen Receptor-beta ligands | ASTRAZENECA AB (SE) | 2005-02-24 | — | — | US | disclosed |
| US-20040039015-A1 | Estrogen Receptor-beta ligands | BARLAAM BERNARD (FR) | 2004-02-26 | — | — | US | disclosed |
| EP-1326593-A1 | ESTROGEN RECEPTOR-$g(b) LIGANDS | AstraZeneca AB (SE) | 2003-07-16 | — | — | EP | disclosed |
| WO-2002030407-A1 | ESTROGEN RECEPTOR-β LIGANDS | ASTRAZENECA AB (SE) | 2002-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043350-A9 | Estrogen Receptor-beta ligands | ESR2, GPER1, ESR1 | NPC1 814/4885HTT 3169/4885LMNA 4303/4885 |
| US-20040039015-A1 | Estrogen Receptor-beta ligands | ESR2, GPER1, ESRRG | NPC1 870/4885HTT 2798/4885LMNA 4363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.